Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid Phleum dose-ranging study in grass pollen allergic rhinitis
2014-004732-19Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of depigoid phleum in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by LETI Pharma. Primary endpoint: Change in Total Nasal Symptom Score after environmental challenge chamber provocation. Started Mar 2015; status: completed.
02
Drugs
depigoid phleum
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2014-004732-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004732-19.